COMPANY PROFILE

VarmX

Explore full profile

Recombinant coagulation therapies addressing urgent bleeding risks

Leiden, NetherlandsFounded 2016Biotech & Life Sciences

Valuation $100–250M Last recorded · 2025

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About VarmX

Developer of therapeutic drugs intended to restore blood clotting in bleeding patients. The company's drugs use modified recombinant human coagulation factor which is capable of restoring blood clotting in the presence of direct factor anticoagulants such as rivaroxaban, apixaban, and edoxaban, enabling physicians to safely and effectively restore hemostasis in case of bleeding.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2016
Headquarters: Leiden, Netherlands
Employees: 32
Open positions: None listed
Dealroom signal: 85.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Patient Care, Spinout, Sustainable Development Goals, EIC, Biotech and Pharma, EIC Fund, Horizon Europe, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	Sep 2025	$117M	$117M	CSL	↗
LATE VCOther financing	Mar 2025	$17M	$165M	EIC Fund	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

VarmX website traffic

Latest recorded traffic for VarmX is 3.9K monthly website visits, up 319.4% over the last three months. VarmX's team grew 10.3% over the past year.

Latest monthly visits3.9K 3-month web change+319.4% 1-year team growth+10.3%

Monthly website visitsNov 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TBTILT BiotherapeuticsTILT Bio aims to enable T-cell treatments and immune checkpoint inhibitors with oncolytic viruses, used to boost lymphocytes and immunological checkpoint blocking antibody treatments	Helsinki, Finland	Operational	27	$67M	$99M
XEXenotheraDeveloping improved immunological treatments using their glyco-humanized antibody platform	Nantes, France	Operational
HYHy2careHy2Care develops the CartRevive Hydrogel implant for treating traumatic cartilage defects, enabling natural healing of the cartilage	Geleen, Netherlands	Operational
BTBetalin therapeuticsBetalin's Micro Pancreas is a revolutionary regenerative micro-organ based on cell therapy. It eliminates the need for daily injections, constant blood glucose monitoring, and dietary constraints	Ramat Gan, Israel	Operational
FRFreezeMFreezeM provides ready-to-use BSF eggs for sustainable, scalable insect farming. FreezeM's technologies decouple the breeding and rearing steps in the insect protein supply chain	Tel Aviv-Yafo, Israel	Operational
NANanoPhoriaNon-viral nanoparticle drug delivery platform for cardiovascular treatments	Milan, Italy	Operational
HOHolloidProvides real-time multi-dimensional data on colloids, based on 3D imaging, with the throughput of cytometry	Vienna, Austria	Operational
ITIntegra TherapeuticsIntegra Therapeutics is a biotech company developing next-generation gene writing tools to cure genetic diseases	Barcelona, Spain	Operational